Ignite Creation Date:
2024-05-06 @ 12:29 AM
Last Modification Date:
2024-10-26 @ 10:50 AM
Study NCT ID:
NCT01586195
Status:
TERMINATED
Last Update Posted:
2017-05-25
First Post:
2012-04-24
Brief Title:
Study Of Zelboraf Vemurafenib in Patients With Locally-Advanced Unresectable Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
An Open-Label Multicenter Phase II Study Of Continuous Oral Zelboraf Vemurafenib in Patients With Locally-Advanced Unresectable Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status:
TERMINATED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Recruitment challenges
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open-label multicenter single-agent phase II study of continuous oral Zelboraf vemurafenib in participants with locally-advanced unresectable stage IIIc or metastatic melanoma and activating exon 15 BRAF mutations other than V600E
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None